Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: NobleGen Biosciences; Exiqon; Waters

NEW YORK (GenomeWeb News) – NobleGen Biosciences has received a $182,000 Phase I SBIR grant from the National Human Genome Research Institute top optimize chemistry for its Optipore sequencing technology. The Concord, Mass.-based firm is developing a nanopore-based method for DNA sequencing by nanopore induced photon emission (SNIPE).

According to GenomeWeb Daily News sister publication Clinical Sequencing News, NobleGen wants to target clinical sequencing tests with its platform and is confident that it will be able to achieve a turnaround time of less than 24 hours for sequencing and assembling a human genome for "significantly less" than $2,000 in total costs, including labor and IT.


Exiqon said this week that the Roswell Park Cancer Institute in Buffalo, NY will serve as a center of excellence, offering real-time PCR services based on Exiqon's mircury LNA Universal RT microRNA PCR product line.


Waters this week said this week that the University of Minnesota's Mass Spectrometry Laboratory has joined the firm's Centers of Innovation Program. The lab is one of 13 Centers of Innovation named by Waters.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more